DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/c93fa6/pipeline_insight) has announced the addition of the "Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market" report to their offering.
Sales of antiepileptic drugs totaled $3.5 billion in 2009 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK). Datamonitor anticipates the combination of continuing strong historical growth dynamics and the uptake of the late-stage pipeline drugs to result in the market value peaking at $5.1 billion in 2017, after which a new wave of patent expiries hits the US.
- Analysis of current epilepsy treatments, unmet market needs and the impact of generics.
- Review of the late-stage epilepsy pipeline, including analysis of key R&D company strategies.
- In depth analysis of historic (20052009) and future (20102019) seven major market sales value dynamics.
- Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019.
Highlights of this title
- With more convenient dosing and a purported improved safety profile over Trileptal and Tegretol, Stedesa (eslicarbazepine, Sepracor/Eisai) is forecast to become the best-selling pipeline antiepileptic drug. Factoring monotherapy approval and first-line use, epilepsy-specific sales are forecast to top $400m across the seven major markets by 2019.
- Rikelta (brivaracetam, UCB) is forecast to generate almost $375m by 2019. With to UCB's already extensive epilepsy portfolio, Datamonitor expects careful positioning will negate significant sales cannibalization. Use will be chiefly among refractory patients with partial seizures, with monotherapy approval important to commercial success.
- Three products are in late-stage development for the at-home management of acute seizures, a market dominated by Diastat (diazepam rectal gel, Valeant). With all seeking to provide an improved administration method, Ikano's intranasal midazolam (ITI-111) is set to become the new market leader with approximately $30m in sales by 2019.
Key reasons to purchase this title
- Analyze competitive environment at time of product launch.
- Validate internal forecasts and market potential for pipeline products.
- Identify licensing opportunities based on company portfolio and market needs.
Key Topics Covered:
1. Pipeline Overview and Dynamics
2. Disease Overview - Market Potential
3. R&D Approach
4. Pipeline Analysis & Forecasts: Ion channel modulators
5. Pipeline Analysis & Forecasts: Glutamate modulators
6. Pipeline Analysis & Forecasts: GABA modulators
7. Pipeline Analysis & Forecasts: Other antiepileptic drugs
8. Pipeline Analysis & Forecasts: Acute epilepsy treatments
9. Innovative Early-Stage Approaches
For more information visit http://www.researchandmarkets.com/research/c93fa6/pipeline_insight
Research and Markets
Laura Wood, Senior Manager,
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
INDUSTRY KEYWORDS: Health Clinical Trials Pharmaceutical